Biotechnology
NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia
SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ -- NeuShen Therapeutics (the "Company"), a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today announced the dosing of the first healthy volunteer inAustralia in t...
Körber Pharma and Siemens Take the Lead in ABI Research's MES Software for Pharmaceutical, Biotechnology, and Cell & Gene Manufacturing Competitive Ranking
LONDON, May 8, 2024 /PRNewswire/ -- The new Competitive Assessment by global technology intelligence firmABI Research provides an in-depth and unbiased examination of the solutions offered by 13 manufacturing execution system (MES) software suppliers targeting pharmaceutical, biotech, and cell & ...
TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain
* The study (NCT05138562) met its primary endpoint of change of dysmenorrhea (menstrual pain) score from baseline to 12 weeks compared to placebo across all tested doses (120 mg, 240 mg, and 320 mg) * Merigolix is expected to emerge as a best-in-class treatment based on its excellent pain re...
Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting
SHANGHAI, May 8, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company focused on autoimmune diseases and oncology, will feature Dr.Lin Shen from Beijing Cancer Hospital at the upcoming ASCO Annual Meeting inChicago. Dr. Shen will present the results f...
Andall Biosciences Introduces 23WELL: A Breakthrough New Brand with Ovary Care Capsules (1+1) as its Stellar Debut Product
SHANGHAI, May 8, 2024 /PRNewswire/ -- Andall Biosciences Inc. (ABI), a renowned biotechnology company at the forefront of life science research and applications, has made a significant stride with the introduction of their groundbreaking new product line, 23WELL. The brand takes center stage with...
NSG BioLabs Fuels Biotech Innovation in Singapore and Southeast Asia Through Partnerships with EnterpriseSG and Merck, Alongside Investments from Celadon Partners and ClavystBio
* Since 2019, NSG BioLabs has been a leader in co-working lab spaces in Singapore, and has nurtured over 40 biotech companies, of which the startups have achieved nearlyUS$400 million funding in total alongside significant business milestones * NSG BioLabs' partnerships with EnterpriseSG and ...
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
GAITHERSBURG, Md., May 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disease...
Seragon Completes Pre-Clinical Study of Aging Intervention Candidate SRN-901
IRVINE, Calif., May 7, 2024 /PRNewswire/ -- Seragon Biosciences, Inc. today announced the completion of a pre-clinical study on its novel anti-aging candidate, SRN-901. This pivotal study, conducted in mice, was undertaken to evaluate the impact of SRN-901 on aging as well as various health marke...
FDA Grants Orphan Drug Designation to 9MW2821
SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Adminis...
Meihua International Medical Technologies Co., Ltd. to Present at the Emerging Growth Conference on May 9, 2024
Meihua International Medical Technologies Co., Ltd. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. YANGZHOU, China, May 7, 2024 /PRNewswire/ -- Meihua International Medical Tech...
Imaging Endpoints Unveils New Initiative with Revolution Endpoints™, an Investment Subsidiary to Accelerate Innovation and Growth
SCOTTSDALE, Ariz., May 7, 2024 /PRNewswire/ -- Imaging Endpoints (IE), a global leader in Imaging CRO technologies and services, has announced the formation of a new subsidiary, Revolution Endpoints, focused on leveraging the Company's strong leadership and financial position to acquire synergist...
Sciwind Biosciences and HK inno.N Corporation Announce Licensing and Partnership Agreement for Ecnoglutide Injection (XW003) in South Korea
HANGZHOU, China and SEOUL, South Korea, May 7, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation, a South Korean commercial stage pharmaceutical company (KOSDAQ: 195940),...
Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis
Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intellig...
GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024
YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual ...
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC)as Monotherapy for Advanced Gastric Cancer
SAN FRANCISCO and SUZHOU, China, May 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
HTL Biotechnology, market leader in biopolymers, acquires the Modern Meadow's human recombinant collagen platform for beauty and biomedical applications
JAVENÉ, France, May 6, 2024 /PRNewswire/ -- HTL Biotechnology strengthens its position as a global leader in the production and development of pharmaceutical-grade biopolymers by acquiring the beauty and biomedical division of American company Modern Meadow (Nutley, NJ). Notably, this acquisitio...
ThinkCyte Launches New Website and Showcases VisionSortTM at Global Events
TOKYO, May 7, 2024 /PRNewswire/ -- ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of itsupdated website. The company will have a presence at the American Society for Immunology (AAI) fromMay 3rd to 7...
21st.BIO unveils a new pilot plant facility to accelerate impact of biotech innovations globally
* Combining world-class industrially proven technology with fermentation capacity, 21st.BIO helps customers get to scale faster, in a risk-mitigated and cost-effective way. * Margrethe Vestager, Executive Vice President of the European Commission, was onsite to inaugurate the pilot facility, ...
Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting
SUZHOU, China, May 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted inChina (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, will be presente...
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
* HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. * Tanfanercept demonstrated statistically significant improvement on the secondary outcome measure, Schirmer testing...
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 317 media titles]
2024-05-07 08:00VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation
[Picked up by 312 media titles]
2024-05-08 14:37OPTIX raises US$15 million fundraising to date to solve the bottleneck of XR optics technology
[Picked up by 306 media titles]
2024-05-08 08:00IN2MF in Kuala Lumpur Presented by Bank Indonesia
[Picked up by 290 media titles]
2024-05-08 16:44